<DOC>
	<DOCNO>NCT01059578</DOCNO>
	<brief_summary>This first study human GSK206136 evaluate effect : good bad , drug human health ( safety tolerability ) amount drug get bloodstream eliminate body ( pharmacokinetics ) . Also study aim investigate penetration drug human brain use PET ( Positron Emission Tomography ) image technology</brief_summary>
	<brief_title>First Study Humans With GSK206136</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Healthy male age 1845 year , limited 2540 year age PET section The subject positive : drug/alcohol , Hepatitis , HIV screen.. The subject history psychiatric illness suicidal attempt behaviour . Abuse alcohol . Clinically significant laboratory , ECG abnormality ; The subject recently receive investigational . Use prescription nonprescription drug , History presence allergy study drug drug class , Donation 500 mL blood within 90 day dose . An unwillingness male subject comply contraceptive requirement Average daily caffeine intake exceed Protocol requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Nk1 Antagonist SSRI</keyword>
	<keyword>Safety</keyword>
	<keyword>First Time Humans</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>